IPSC · Century Therapeutics, Inc. · Documents

$1.63 -0.11 (-6.32%) At close · Nov 12

Russell 2000 member Rebalance outlook locked

Market Cap

$296.00M

181.60M

Volume · Nov 12 608.76K Avg daily vol (3M) 719.15K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $109.16M up 1556.8% 10-K filed Mar 12, 2026 Quarterly report New FY2026 Q3 Net loss $23.45M 10-Q filed Nov 12, 2026 Latest results New Financial results 8-K filed Nov 12, 2026

2026

Nov 12

Current report 8-K

Financial results AI summary on its way

Nov 12

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Quarterly report for FY2026 Q3 AI summary on its way

Net loss $23.45M Diluted EPS -$0.11

Oct 2

Current report 8-K

Regulation FD disclosure, Other events

Century Therapeutics reported CNTY-813 sustained glycemic control for over eleven months, showed consistent production across five clinical-scale batches, and remained functional after 96 hours of cold storage; IND submission is targeted for Q4 2026 and initial clinical data for 2H 2027.

Sep 9

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure AI summary on its way

Aug 12

Current report 8-K

Financial results, Regulation FD disclosure AI summary on its way

Aug 12

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Net loss $34.55M Diluted EPS -$0.17

Jun 16

Current report 8-K Events of Jun 15

Director or officer change, or executive pay AI summary on its way

Jun 12

Current report 8-K Events of Jun 11

Charter or bylaw amendment, or fiscal year change, Shareholder vote results AI summary on its way

Jun 8

Current report 8-K

Other events AI summary on its way

May 13

Current report 8-K

Financial results AI summary on its way

May 13

Quarterly report 10-Q FY2026 Q1, ended Mar 31

Quarterly report for FY2026 Q1 AI summary on its way

Net loss $21.65M Diluted EPS -$0.11

Apr 27

Proxy statement DEF 14A Meeting Jun 11, 2026

Proxy statement AI summary on its way

Apr 27

Proxy statement DEFA14A

Proxy statement AI summary on its way

Apr 16

Annual report to holders ARS

Annual report to holders AI summary on its way

Apr 16

Proxy statement PRE 14A Meeting Jun 11, 2026

Proxy statement AI summary on its way

Mar 26

Current report 8-K

Other events AI summary on its way

Mar 12

Current report 8-K

Financial results, Regulation FD disclosure AI summary on its way

Mar 12

Annual report 10-K FY2025, ended Dec 31

Annual report for FY2025 AI summary on its way

Revenue $109.16M ▲ 1556.8% Net loss $9.58M Diluted EPS -$0.14

Feb 5

Registration statement S-3

Registration statement AI summary on its way

Jan 23

Current report 8-K Events of Jan 22

Shareholder vote results, Other events AI summary on its way

Jan 12

Current report 8-K

Regulation FD disclosure AI summary on its way

Jan 8

Current report 8-K Events of Jan 7

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure AI summary on its way

Jan 5

Registration statement S-3/A

Registration statement AI summary on its way

2025

Dec 29

Current report 8-K Events of Dec 18

Director or officer change, or executive pay

Dec 12

Current report 8-K

Regulation FD disclosure

Dec 9

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Dec 2

Proxy statement DEF 14A Meeting Jan 22, 2026

Proxy statement

Dec 2

Proxy statement DEFA14A

Proxy statement

Nov 21

Proxy statement PRE 14A Meeting Jan 22, 2026

Proxy statement

Nov 13

Current report 8-K

Financial results, Regulation FD disclosure, Other events

Nov 13

Quarterly report 10-Q FY2025 Q3, ended Sep 30

Quarterly report for FY2025 Q3

Net loss $34.42M Diluted EPS -$0.40

Aug 29

Current report 8-K Events of Aug 27

Delisting notice or listing transfer

Aug 14

Current report 8-K Events of Aug 13

Financial results, Director or officer change, or executive pay, Regulation FD disclosure

Aug 14

Quarterly report 10-Q FY2025 Q2, ended Jun 30

Quarterly report for FY2025 Q2

Net loss $32.54M Diluted EPS -$0.38

Jul 10

Registration statement S-3

Registration statement

Jul 7

Current report 8-K Events of Jul 1

Exit or restructuring costs, Director or officer change, or executive pay

Jun 16

Current report 8-K Events of Jun 12

Shareholder vote results

May 15

Current report 8-K

Financial results, Regulation FD disclosure

May 15

Quarterly report 10-Q FY2025 Q1, ended Mar 31

Quarterly report for FY2025 Q1

Revenue $109.16M ▲ 12667.7% Net income $76.56M Diluted EPS $0.89

Apr 22

Proxy statement DEF 14A Meeting Jun 12, 2025

Proxy statement

Apr 22

Annual report to holders ARS

Annual report to holders

Apr 22

Proxy statement DEFA14A

Proxy statement

Mar 19

Current report 8-K

Financial results, Regulation FD disclosure

Mar 19

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $6.59M ▲ 194.8% Net loss $126.57M Diluted EPS -$1.61

Feb 28

Current report 8-K Events of Feb 26

Delisting notice or listing transfer

Jan 13

Current report 8-K

Financial results, Regulation FD disclosure

2024

Dec 13

Current report 8-K Events of Dec 12

Ended a material agreement

Nov 5

Current report 8-K

Financial results, Other events

Nov 5

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $791K ▲ 434.5% Net loss $31.23M Diluted EPS -$0.37

Sep 26

Current report 8-K

Director or officer change, or executive pay

Showing 1–50 of 127 documents

Key facts CIK 1850119 CUSIP 15673T100 13F (30d) 55 filings 41 filers Visit website Investor relations